Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Debate On Antiplatelet Gene Testing Continues; First Point-Of-Care Test Filed

Executive Summary

The first regulatory application for a point-of-care assay for genotyping patients for response to antiplatelet therapy was submitted at the end of August - if Nanosphere's test is approved, it could make genotyping a more feasible routine tool for guiding therapy for Plavix
Advertisement

Related Content

Will Plavix Testing Be Enough To Limit Use Of Newer Antiplatelet Drugs?
Will Plavix Testing Be Enough To Limit Use Of Newer Antiplatelet Drugs?
Clotbusting On The Clock: New Brands Must Establish Themselves Before Improved Plavix Diagnostics Do
Clotbusting On The Clock: New Brands Must Establish Themselves Before Improved Plavix Diagnostics Do
Accumetrics Teams Up With Big Pharma To Push Platelet Function Testing
Routine Gene Testing For Plavix Patients Unsupported By Evidence - ACC/AHA
Personalizing Plavix: Eric Topol Champions Genotyping For Stent Patients
Personalizing Plavix: Eric Topol Champions Genotyping For Stent Patients

Topics

Advertisement
UsernamePublicRestriction

Register

PS052578

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel